Intervention

Irinotecan

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 47 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials47
Recruiting6
Common conditions25
Lead sponsors shown15
Advertisement

Clinical trials

47 shown
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)NCT07155200 · 2025-12-18
RECRUITING
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06954246 · 2025-06-04
RECRUITING
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCNCT06496048 · 2024-09-14
RECRUITING
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsNCT06586515 · 2024-09-12
RECRUITING
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)NCT05319730 · 2023-05-16
RECRUITING
Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerNCT05800587 · 2023-02-22
RECRUITING
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsNCT06607185 · 2024-10-21
ACTIVE_NOT_RECRUITING
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)NCT05049863 · 2023-02-27
TERMINATED
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)NCT05731518 · 2023-02-23
UNKNOWN
SMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30
WITHDRAWN
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung CancerNCT05595889 · 2022-12-01
UNKNOWN
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)NCT05342636 · 2022-07-27
COMPLETED
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)NCT05153239 · 2022-07-22
COMPLETED
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)NCT05239741 · 2022-04-02
ACTIVE_NOT_RECRUITING
Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st ChemotherapyNCT04985201 · 2021-11-01
UNKNOWN
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy(Irinotecan Plus Platinum)and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer(SCLC)NCT04453930 · 2020-06-08
UNKNOWN
9-ING-41 in Patients With Advanced CancersNCT03678883 · 2019-01-04
ACTIVE_NOT_RECRUITING
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung CancerNCT03651219 · 2018-09-08
UNKNOWN
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)NCT03374254 · 2018-02-16
COMPLETED
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung CancerNCT03098030 · 2017-06-01
COMPLETED
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable CancerNCT03009058 · 2017-05-31
TERMINATED
Irinotecan for Advanced and Metastatic Breast CancerNCT03562390 · 2017-04-01
UNKNOWN
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)NCT02720068 · 2016-05-02
COMPLETED
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)NCT02489903 · 2015-06-01
COMPLETED
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)NCT02423954 · 2015-04-01
TERMINATED
Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung CancerNCT02348450 · 2015-02-01
UNKNOWN
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)NCT02331251 · 2014-12-01
TERMINATED
Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLCNCT02275806 · 2014-10-01
TERMINATED
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer PatientsNCT01941316 · 2013-11-01
COMPLETED
A Protocol of Irinotecan for Carcinoma of the LungNCT01654081 · 2013-10-01
WITHDRAWN
Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung CancerNCT01977235 · 2013-09-01
UNKNOWN
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid TumorsNCT01803282 · 2013-03-29
COMPLETED
Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung CancerNCT01635400 · 2012-06-01
UNKNOWN
Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung CancerNCT01607554 · 2012-04-01
TERMINATED
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced CancersNCT01451632 · 2011-10-01
COMPLETED
A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)NCT00874328 · 2008-10-01
UNKNOWN
RSHF in Colorectal CancerNCT01220063 · 2007-10-19
COMPLETED
Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IVNCT00614965 · 2006-11-01
COMPLETED
Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)NCT00452634 · 2006-04-01
COMPLETED
Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLCNCT00319800 · 2006-02-01
UNKNOWN
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00057837 · 2004-07-14
COMPLETED
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and CapecitabineNCT00072852 · 2003-11-01
COMPLETED
Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung CancerNCT00193375 · 2003-08-01
COMPLETED
Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung CancerNCT00264134 · 2003-06-01
TERMINATED
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung CancerNCT00139711 · 2003-03-01
COMPLETED
Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung CancerNCT00193349 · 2002-09-01
COMPLETED
Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung CancerNCT00819728 · 2000-06-01
COMPLETED

Common conditions

Mapped diseases appearing in these trials

Shared study participation does not establish that this intervention treats a disease.

Trial status mix

COMPLETED18
UNKNOWN11
TERMINATED7
RECRUITING6
ACTIVE_NOT_RECRUITING3
WITHDRAWN2

Phase mix

PHASE233
PHASE118
PHASE36
EARLY_PHASE11
PHASE41
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.